GO:0042166 acetylcholine binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0042166 acetylcholine binding is a molecular function defined as binding to acetylcholine, the neurotransmitter released at parasympathetic synapses and neuromuscular junctions.
• Acetylcholine binding is mediated by nicotinic acetylcholine receptors (nAChRs), muscarinic acetylcholine receptors (mAChRs), the vesicular acetylcholine transporter (VAChT), and acetylcholine-binding proteins (AChBPs) [1,3,4,5].
• The binding site of nicotinic receptors is located at the interface of extracellular domains and involves aromatic residues that stabilize the ligand through cation-pi and electrostatic interactions [5,6,8].
• Structural transitions in acetylcholine receptors during muscle development reveal distinct subunit compositions and binding properties that can be targeted experimentally.
• Cholinergic modulation through acetylcholine binding influences dopamine release and effortful behavior, linking this molecular function to circuit-level physiology.
• Dysregulation of acetylcholine binding is implicated in neurodegenerative diseases such as Alzheimer's disease and myasthenia gravis, making it a key target for therapeutic and CRISPR-based research [1,5].
Description
Acetylcholine binding (GO:0042166) is a molecular function that describes the selective interaction of a protein with acetylcholine, an acetic acid ester of choline that serves as a neurotransmitter at parasympathetic synapses and neuromuscular junctions. This binding event is the first step in cholinergic signaling and is essential for converting a chemical signal into a cellular response [2,5]. The function is executed by a diverse set of proteins, including nicotinic acetylcholine receptors (nAChRs), muscarinic acetylcholine receptors (mAChRs), the vesicular acetylcholine transporter (VAChT), and soluble acetylcholine-binding proteins (AChBPs) [1,3,4,5]. Each of these proteins recognizes acetylcholine through distinct structural motifs, but they share the fundamental property of binding this small molecule with high specificity [5,6]. Researchers study acetylcholine binding to understand synaptic transmission, muscle contraction, and higher brain functions such as attention and reward [3,7]. Because acetylcholine binding is central to both normal physiology and disease, it is a prime target for genetic and pharmacological interventions [1,4].
acetylcholine binding At A Glance
| GO ID | GO:0042166 |
|---|---|
| GO term | acetylcholine binding |
| Ontology | molecular_function |
| Synonym | none |
| Definition | Binding to acetylcholine, an acetic acid ester of the organic base choline that functions as a neurotransmitter, released at the synapses of parasympathetic nerves and at neuromuscular junctions. |
| Major function | Neurotransmitter recognition and initiation of cholinergic signaling |
| Key protein families | Nicotinic acetylcholine receptors, muscarinic acetylcholine receptors, vesicular acetylcholine transporter, acetylcholine-binding proteins |
| Cellular location | Plasma membrane, synaptic vesicles, neuromuscular junction |
| Representative ligands | Acetylcholine, nicotine, carbachol, antagonists such as curare and atropine |
What Is GO:0042166?
In our own words, acetylcholine binding (GO:0042166) is the molecular function of a protein or protein complex physically interacting with acetylcholine. This interaction is non-covalent and reversible, and it occurs at defined binding sites within the protein. The function is defined by the ability to bind acetylcholine, regardless of whether the binding leads to ion channel opening, G-protein activation, or transport. It is a molecular function term in the Gene Ontology, distinct from the biological processes or cellular components in which acetylcholine binding participates.
Why Is acetylcholine binding Important in Cell Biology?
Acetylcholine binding is a fundamental molecular event that underlies all cholinergic neurotransmission, influencing muscle contraction, heart rate, glandular secretion, and cognitive processes such as learning and memory [2,5]. Dysfunction of acetylcholine binding is associated with neurological and muscular disorders, including Alzheimer's disease, Parkinson's disease, myasthenia gravis, and congenital myasthenic syndromes [1,5]. Understanding the structural and mechanistic details of acetylcholine binding enables the design of drugs that modulate cholinergic signaling, such as nicotinic agonists for cognitive enhancement or antagonists for muscle relaxation [1,8]. Moreover, acetylcholine binding is a model system for studying ligand-gated ion channels and allosteric modulation, with broad implications for drug discovery [1,6].
• Acetylcholine binding initiates excitatory or inhibitory signals at neuromuscular junctions and autonomic synapses [2,5].
• It is essential for muscle contraction and movement, as seen in developing muscle where receptor subunit switching alters binding properties.
• Cholinergic modulation via acetylcholine binding regulates dopamine release and effortful behavior, linking it to motivation and reward circuits.
• Nicotinic acetylcholine receptors are targets for smoking cessation drugs and cognitive enhancers.
• Muscarinic acetylcholine receptors are involved in memory and are targets for Alzheimer's disease therapeutics.
• The vesicular acetylcholine transporter (VAChT) binds acetylcholine for storage in synaptic vesicles, and its antagonism affects cholinergic transmission.
• Acetylcholine-binding proteins (AChBPs) from invertebrates serve as structural surrogates for studying ligand recognition.
• Mutations in acetylcholine receptor subunits cause congenital myasthenic syndromes, highlighting the clinical relevance of binding.
• Acetylcholine binding is a key parameter in pharmacokinetic and pharmacodynamic studies of cholinergic drugs [1,8].
• CRISPR-based editing of genes encoding acetylcholine-binding proteins enables precise functional dissection of binding sites [3,4].
What Happens During acetylcholine binding?
Ligand recognition and initial contact
In simple terms: Acetylcholine floats near the protein and is recognized by a specific pocket on the protein surface.
The binding process begins when acetylcholine diffuses into the vicinity of the binding site. The binding pocket is typically lined with aromatic residues that create a complementary surface for the positively charged quaternary ammonium group of acetylcholine [5,6]. Electrostatic interactions between the ligand and the protein, including cation-pi interactions, provide the initial driving force for recognition. This step is reversible and depends on the local concentration of acetylcholine, which is tightly regulated by synthesis, release, and degradation.
Conformational changes and stabilization
In simple terms: Once acetylcholine docks, the protein changes shape to hold it tightly.
Upon binding, the protein undergoes conformational changes that stabilize the ligand-protein complex. In nicotinic acetylcholine receptors, this involves movements of the extracellular domain loops that close around the ligand. Structural studies of muscle acetylcholine receptors during development have revealed that subunit composition influences these conformational transitions, affecting binding affinity and channel gating. The binding energy is derived from a combination of hydrogen bonds, van der Waals forces, and electrostatic interactions, as shown by computational studies on nicotine binding to acetylcholine-binding protein.
Signal initiation or transport
In simple terms: The binding event triggers a cellular response, such as opening a channel or moving the neurotransmitter.
For ionotropic nicotinic receptors, acetylcholine binding causes the channel pore to open, allowing ions to flow across the membrane and depolarize the cell. For metabotropic muscarinic receptors, binding activates G-proteins that modulate downstream effectors. In the case of the vesicular acetylcholine transporter (VAChT), binding is coupled to transport of acetylcholine into synaptic vesicles, a process that has been structurally characterized and shown to be antagonized by specific inhibitors. Each of these outcomes depends on the precise binding interaction.
Allosteric modulation and regulation
In simple terms: Other molecules can bind at different sites and change how well acetylcholine binds or how strongly it signals.
Acetylcholine binding can be modulated by allosteric ligands that bind to sites distinct from the orthosteric site. For example, alpha7 nicotinic acetylcholine receptors can be potentiated or activated by allosteric agonists, which alter the receptor's response to acetylcholine. This allosteric regulation is important for fine-tuning cholinergic signaling and is a target for drug development. Additionally, post-translational modifications and protein-protein interactions can influence the binding affinity and efficacy.
Key Genes Involved in GO:0042166 acetylcholine binding
The following genes encode proteins that directly bind acetylcholine or are essential for its binding function, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CHRNA1 | Nicotinic acetylcholine receptor alpha1 subunit; forms the ligand-binding site in muscle | Mutations cause congenital myasthenic syndromes; target for muscle relaxants [3,5] |
| CHRNB1 | Nicotinic acetylcholine receptor beta1 subunit; structural component of muscle receptor | Required for assembly and function of muscle nAChR; studied in development |
| CHRND | Nicotinic acetylcholine receptor delta subunit; contributes to ligand-binding site | Mutations linked to myasthenia gravis; important for receptor maturation |
| CHRNE | Nicotinic acetylcholine receptor epsilon subunit; replaces gamma in adult muscle | Subunit switch affects binding properties; mutations cause congenital myasthenia |
| CHRNG | Nicotinic acetylcholine receptor gamma subunit; fetal muscle receptor | Critical for fetal development; studied for subunit switching |
| CHRNA7 | Alpha7 nicotinic receptor; homomeric receptor with high calcium permeability | Target for cognitive enhancement and allosteric modulation |
| CHRNA4 | Alpha4 nicotinic receptor subunit; forms heteromeric receptors with beta2 | Implicated in nicotine addiction and epilepsy; drug target |
| CHRNB2 | Beta2 nicotinic receptor subunit; partner of alpha4 | Key for high-affinity nicotine binding; knockout models available |
| CHRM1 | Muscarinic acetylcholine receptor M1; G-protein coupled | Involved in memory and Alzheimer's disease; target for agonists |
| CHRM2 | Muscarinic acetylcholine receptor M2; mediates bradycardia | Studied for heart rate regulation and cognitive functions |
| SLC18A3 | Vesicular acetylcholine transporter (VAChT); packages acetylcholine into vesicles | Structural studies reveal binding mechanism; target for inhibitors |
| ACHE | Acetylcholinesterase; hydrolyzes acetylcholine, terminating binding | Inhibitors used in Alzheimer's disease; regulates ligand availability |
| CHAT | Choline acetyltransferase; synthesizes acetylcholine | Essential for acetylcholine production; knockout models affect binding |
| LYNX1 | Lynx1; allosteric modulator of nicotinic receptors | Modulates acetylcholine binding and receptor function |
| RIC3 | Resistance to inhibitors of cholinesterase 3; chaperone for nAChR assembly | Required for functional expression of alpha7 receptors |
| BCHE | Butyrylcholinesterase; hydrolyzes acetylcholine in plasma | Modulates acetylcholine levels; genetic variants affect drug metabolism |
| AChBP | Acetylcholine-binding protein from invertebrates; structural homolog of nAChR ligand-binding domain | Model system for studying ligand binding |
How Is acetylcholine binding Regulated?
Acetylcholine binding is regulated at multiple levels. The availability of acetylcholine is controlled by synthesis via choline acetyltransferase (CHAT) and degradation by acetylcholinesterase (ACHE) and butyrylcholinesterase (BCHE). Receptor expression and subunit composition are developmentally regulated, as seen in muscle where the gamma subunit is replaced by epsilon, altering binding kinetics. Allosteric modulators, such as Lynx1, can enhance or inhibit binding. Additionally, the vesicular acetylcholine transporter (VAChT) regulates the storage and release of acetylcholine, indirectly affecting binding at the synapse. These regulatory mechanisms ensure precise control of cholinergic signaling.
acetylcholine binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CHRNA1 | Congenital myasthenic syndrome | Knock-in mouse with patient mutation; point mutation in cell line |
| CHRNE | Congenital myasthenia gravis | Knockout mouse; overexpression of mutant subunit |
| CHRNA7 | Schizophrenia, cognitive deficits | Knockout mouse; allosteric modulator testing |
| SLC18A3 | Cholinergic deficiency | Conditional knockout; VAChT inhibitor studies |
| ACHE | Alzheimer's disease | Knockout mouse; overexpression for drug screening |
Myasthenia gravis and congenital myasthenic syndromes
Myasthenia gravis is an autoimmune disease in which antibodies target nicotinic acetylcholine receptors at the neuromuscular junction, impairing acetylcholine binding and causing muscle weakness. Congenital myasthenic syndromes are caused by mutations in genes encoding acetylcholine receptor subunits, such as CHRNA1, CHRNB1, CHRND, and CHRNE, leading to defective binding or channel gating. These conditions highlight the critical role of acetylcholine binding in muscle function.
Alzheimer's disease and cognitive decline
Alzheimer's disease is characterized by loss of cholinergic neurons and reduced acetylcholine levels, which impairs acetylcholine binding and cholinergic signaling. Current therapies include acetylcholinesterase inhibitors that increase acetylcholine availability, indirectly enhancing binding. Nicotinic and muscarinic receptors are targets for developing cognitive enhancers [1,5].
Addiction and neurological disorders
Nicotinic acetylcholine receptors, particularly those containing alpha4 and beta2 subunits, are involved in nicotine addiction. Alpha7 nicotinic receptors are implicated in schizophrenia and inflammation. Cholinergic modulation of dopamine release via acetylcholine binding influences effortful behavior, linking this molecular function to motivation and reward.
From acetylcholine binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does a specific point mutation alter acetylcholine binding affinity? | Point mutation knock-in cell line (e.g., HEK293) expressing mutant receptor |
| What is the effect of complete loss of a receptor subunit? | Knockout mouse or knockout cell line |
| How does a disease-associated mutation affect receptor function? | Knock-in mouse carrying human mutation |
| Where is the receptor expressed and how does it traffic? | Tagged knock-in (e.g., GFP) for imaging |
| Can overexpression of a subunit enhance acetylcholine binding? | Overexpression cell line or transgenic mouse |
| What genes are essential for acetylcholine binding in a specific tissue? | CRISPR library screening in relevant cell type |
How to Study the acetylcholine binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding | Affinity and number of binding sites | Characterizing receptor subtypes and drug candidates |
| Surface plasmon resonance | Real-time binding kinetics | Measuring association and dissociation rates |
| Cryo-EM | High-resolution structure of ligand-receptor complex | Visualizing binding pocket and conformational changes |
| Patch-clamp | Ion channel activity upon ligand binding | Functional analysis of nicotinic receptors |
| CRISPR knockout screen | Genes required for acetylcholine binding | Identifying novel regulators in cell models |
| Immunofluorescence | Subcellular localization of binding proteins | Tissue distribution and trafficking studies |
| Isothermal titration calorimetry | Thermodynamics of binding | Quantifying binding enthalpy and entropy |
Binding assays
Radioligand binding assays using tritiated acetylcholine or nicotinic agonists measure binding affinity (Kd) and receptor density (Bmax) in membrane preparations or intact cells [2,5]. These assays are fundamental for characterizing acetylcholine-binding proteins and for screening drugs that compete for the binding site.
Structural biology
X-ray crystallography and cryo-electron microscopy have resolved the structures of acetylcholine-binding proteins and nicotinic receptors, revealing the atomic details of the binding pocket [3,4,8]. These methods show how acetylcholine and other ligands interact with specific residues, guiding mutagenesis studies.
Electrophysiology
Patch-clamp and two-electrode voltage-clamp recordings measure ion channel currents elicited by acetylcholine binding, providing functional readouts of receptor activation and modulation [1,5]. This is essential for understanding how binding translates into electrical signals.
CRISPR-based genetic screens
Genome-wide CRISPR knockout or activation screens can identify genes that regulate acetylcholine binding or cholinergic signaling. For example, screens in neuronal cell lines can uncover novel modulators of receptor expression or function [3,4].
How CRISPR Can Be Used to Study GO:0042166 acetylcholine binding
Knockout
CRISPR knockout of genes encoding acetylcholine-binding proteins, such as CHRNA1 or CHRM1, eliminates the binding function and allows researchers to study downstream effects on signaling and physiology [3,5]. Knockout cell lines and mice are valuable for validating drug targets and understanding compensatory mechanisms.
Point Mutation
Introducing specific point mutations in the binding pocket, such as those found in congenital myasthenic syndromes, enables precise dissection of residues critical for acetylcholine binding. Point mutation models can reveal how single amino acid changes alter affinity, efficacy, and allosteric modulation.
Knock-in
Knock-in of tagged or humanized versions of acetylcholine-binding proteins allows visualization and functional analysis in vivo. For example, tagging CHRNA7 with fluorescent proteins enables tracking of receptor trafficking and localization. Knock-in of disease-associated mutations recapitulates human pathology in animal models.
Overexpression
Overexpression of acetylcholine-binding proteins in cell lines or transgenic animals increases the number of binding sites, facilitating biochemical and pharmacological studies. Overexpression can also reveal gain-of-function phenotypes and enhance signal transduction.
How EDITGENE Supports acetylcholine binding Research
Researchers studying acetylcholine binding-related genes often need to determine whether a candidate gene is causally involved in binding, signaling, or disease. This requires precise genetic models that can isolate the contribution of individual genes and mutations. EDITGENE provides a comprehensive suite of CRISPR services to accelerate such studies, from knockout to knock-in and library screening.
Contact EDITGENE today to design your custom CRISPR model for acetylcholine binding research.
Frequently Asked Questions About acetylcholine binding
What is acetylcholine binding?
Acetylcholine binding is a molecular function (GO:0042166) where a protein interacts with acetylcholine, a neurotransmitter, to initiate signaling or transport [2,5].
What genes are involved in acetylcholine binding?
Key genes include CHRNA1, CHRNB1, CHRND, CHRNE, CHRNG, CHRNA7, CHRNA4, CHRNB2, CHRM1, CHRM2, SLC18A3, ACHE, CHAT, and BCHE [3,4,5].
What is the GO term for acetylcholine binding?
The Gene Ontology term is GO:0042166, defined as binding to acetylcholine, an acetic acid ester of choline that functions as a neurotransmitter.
How does acetylcholine bind to nicotinic receptors?
Acetylcholine binds at the interface of extracellular domains of nicotinic receptors, stabilized by aromatic residues and electrostatic interactions, leading to channel opening [5,6,8].
What diseases are associated with defective acetylcholine binding?
Myasthenia gravis, congenital myasthenic syndromes, Alzheimer's disease, and schizophrenia are linked to altered acetylcholine binding [1,3,5].
What methods are used to study acetylcholine binding?
Common methods include radioligand binding assays, cryo-EM, patch-clamp electrophysiology, and CRISPR screens [2,3,4,5].
What is the vesicular acetylcholine transporter?
VAChT (SLC18A3) binds acetylcholine and transports it into synaptic vesicles; its structure and antagonism have been characterized.
How does acetylcholine binding affect dopamine release?
Cholinergic modulation via acetylcholine binding on nicotinic receptors can drive dopamine release, influencing effortful behavior.
Can CRISPR be used to study acetylcholine binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable precise genetic dissection of acetylcholine binding proteins [3,4].
What is the role of acetylcholine-binding protein (AChBP)?
AChBP is a soluble invertebrate homolog of the nicotinic receptor ligand-binding domain, used as a model to study ligand recognition.
Conclusion
Acetylcholine binding (GO:0042166) is a central molecular function in cholinergic neurotransmission, mediated by a diverse array of receptors and transporters. Its structural and mechanistic details have been elucidated through decades of research, revealing how a small neurotransmitter can trigger profound physiological effects. Dysregulation of acetylcholine binding underlies numerous diseases, making it a prime target for therapeutic intervention. CRISPR-based models offer powerful tools to dissect the genetic basis of acetylcholine binding and to develop novel treatments.
References
- 1. Sanders VR et al.. 2023. Potentiation and allosteric agonist activation of α7 nicotinic acetylcholine receptors: binding sites and hypotheses.. Pharmacol Res 191:106759 PMID: 37023990
- 2. BRODKIN E et al.. 1953. Binding of acetylcholine.. Am J Physiol 173(3):437-42 PMID: 13065467
- 3. Li H et al.. 2024. Structural switch in acetylcholine receptors in developing muscle.. Nature 632(8027):1174-1180 PMID: 39085615
- 4. Ma Q et al.. 2025. Binding mechanism and antagonism of the vesicular acetylcholine transporter VAChT.. Nat Struct Mol Biol 32(5):818-827 PMID: 39806024
- 5. Arias HR. 1997. Topology of ligand binding sites on the nicotinic acetylcholine receptor.. Brain Res Brain Res Rev 25(2):133-91 PMID: 9403137
- 6. Luyten WH. 1986. A model for the acetylcholine binding site of the nicotinic acetylcholine receptor.. J Neurosci Res 16(1):51-73 PMID: 3528512
- 7. Touponse GC et al.. 2026. Cholinergic modulation of dopamine release drives effortful behaviour.. Nature 651(8107):1020-1029 PMID: 41606339
- 8. Li Z et al.. 2022. Electrostatic Contributions to the Binding Free Energy of Nicotine to the Acetylcholine Binding Protein.. J Phys Chem B 126(43):8669-8679 PMID: 36260486
